PT  - JOURNAL ARTICLE
AU  - Ethan G. Brown
AU  - Lana M. Chahine
AU  - Samuel M. Goldman
AU  - Monica Korell
AU  - Emerald Mann
AU  - Daniel R. Kinel
AU  - Vanessa Arnedo
AU  - Kenneth L. Marek
AU  - Caroline M. Tanner
TI  - The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
AID  - 10.1101/2020.07.14.20153023
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.14.20153023
4099  - http://medrxiv.org/content/early/2020/07/17/2020.07.14.20153023.short
4100  - http://medrxiv.org/content/early/2020/07/17/2020.07.14.20153023.full
AB  - Objective To rapidly identify areas of need and improve care in people with Parkinson’s disease (PwPD) affected by the COVID-19 pandemic, we deployed a survey focusing on the presentation and complications of COVID-19 infection and the effect of the COVID-19 pandemic among those not infected.Methods Individuals with and without PD participating in the online study Fox Insight (FI) were invited to complete an online survey between April 23-May 23, 2020. Among people reporting COVID-19 diagnosis, we compared the frequency of symptoms and poor outcomes in people with and without PD. Among people not reporting COVID-19, we assessed the effects of the pandemic on access to medical care and other services, and in PwPD, its effects on PD symptoms.Results Among 5,429 PwPD and 1,452 without PD, 77 reported a COVID-19 diagnosis (51 PwPD, 26 without PD). Complications were more frequent in people with longer PD duration. PwPD and COVID-19 experienced new or worsening motor (63%) and nonmotor (75%) PD symptoms. PwPD not diagnosed with COVID-19 reported disrupted medical care (64%), exercise (21%), and social activities (57%), and worsened PD motor (43%) and non-motor (52%) symptoms. Disruptions were more common for PwPD living alone, and for those with lower income and non-white race.Conclusions The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk. FI provides a rapid, patient-centered means to assess these effects and identify needs that can be used to improve the health of PwPD.Competing Interest StatementE. G. Brown receives research support from the Michael J. Fox Foundation and the Gateway Institute for Brain Research Inc. He has received research support from Biogen Inc within the last two years. He has received honorarium from NEJM Knowledge+ as the Neurology Section Editor, and has received consulting fees from Oscar Health and Rune Labs Inc within the last two years. L. M. Chahine receives research support from the Michael J Fox Foundation, UPMC Competitive Medical Research Fund, and University of Pittsburgh, is study site investigator for a study sponsored by Biogen, receives research support from the National Institutes of Health, receives royalties from Elsevier (for authorship), and receives royalties from Wolters Kluwel (for authorship). S. M. Goldman's research is supported by grants from the Michael J. Fox Foundation, VA CSR&D Merit, ATSDR/CDC, NIOSH, Department of Defense, Biogen Inc, UCSF Academic Senate M. Korell receives research support from the Michael J. Fox Foundation E. Mann reports nothing to disclose. D. Kinel reports nothing to disclose. V. Arnedo is an employee of The Michael J. Fox Foundation for Parkinson's Research. K. Marek reports grants from the Michael J Fox Foundation, Dept of Defense and personal fees from GE Healthcare, Roche, Neuropore, Proclara, UCB, Lysosomal Therapeutics, Inc, Neuroderm, Denali, Takeda, Samumed, Cerapsir, HANDL, Samus, Biohaven, Neuron23, Aprinoia, Genentech, Invicro C. M. Tanner reports grants from Parkinson Foundation, Gateway LLC, Roche/Genentech, Parkinson Study Group, Michael J Fox Foundation, NIH/NIA, NIH/NINDS, VA Merit, Dept of Defense, Biogen Idec, Roche Genentech and personal fees from Biogen Idec, Acorda, Adamas Therapeutics, Amneal, CNS Ratings, Grey Matter LLC, Northwestern University, Partners, Harvard U, Guidemark Health, Acadia, Neurocrine, Lundbeck and Cadent.   Clinical TrialThis is a survey conducted in Fox Insight, online platform supported by the Michael J Fox Foundation, https://www.foxinsight.michaeljfox.orgClinical Protocols https://www.foxden.michaeljfox.org Funding StatementThis work is supported by grant support provided by the Michael J Fox Foundation to the University of California. The Principal Investigator is Caroline Tanner MD, PhD at UCSF, and includes support for effort of Ethan Brown, MD, Monica Korell and Emerald Mann. Vanessa Arnedo is an employee of the Michael J Fox Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Fox Insight study and the survey for this COVID-19 study were approved by the New England IRB and informed consent was obtained online from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll survey questions and data are available for download online at: https://www.foxden.michaeljfox.org. https://www.foxden.michaeljfox.org. https://www.foxinsight.michaeljfox.org